BioRestorative Therapies, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted NPV (rNPV) of pipeline: $150M estimated peak annual US sales for BRTX-100 (autologous stem-cell therapy for chronic lumbar disc disease, Phase 2 data expected 2027) x 7% probability of eventual approval x a 1.0x peak-sales value multiplier, discounted 6 years to approval/launch at a 20% biotech discount rate, divided by 1.27M shares outstanding.

Reasoning: BioRestorative is a pre-revenue, single-asset clinical-stage biotech whose value depends almost entirely on binary Phase 2 trial success, so a probability-weighted (risk-adjusted) NPV of the pipeline is the standard and most appropriate valuation method for this type of company rather than a conventional cash-flow DCF.